Michael Rudnicki
Founder at SATELLOS BIOSCIENCE INC.
Net worth: 1 M $ as of 2024-04-29
Michael Rudnicki active positions
Companies | Position | Start | End |
---|---|---|---|
SATELLOS BIOSCIENCE INC. | Founder | 2017-12-31 | - |
Corporate Officer/Principal | - | - | |
Director/Board Member | - | 2021-12-04 | |
Chief Tech/Sci/R&D Officer | 2018-04-30 | - | |
University of Ottawa | Corporate Officer/Principal | - | - |
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute Hospital/Nursing ManagementHealth Services The Ottawa Hospital Research Institute is based in Ottawa, CA. The Canadian company provides world-class care with compassionate people. | Corporate Officer/Principal | - | - |
Stem Cell Network | Corporate Officer/Principal | - | - |
Career history of Michael Rudnicki
Former positions of Michael Rudnicki
Companies | Position | Start | End |
---|---|---|---|
Verio Therapeutics, Inc.
Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Founder | - | - |
The Ontario Institute For Regenerative Medicine
The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada. | Director/Board Member | - | - |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Director/Board Member | 2017-12-31 | - |
Chief Tech/Sci/R&D Officer | 2017-12-31 | - | |
Founder | 2017-12-31 | - | |
FATE THERAPEUTICS, INC. | Founder | 2007-04-26 | - |
Training of Michael Rudnicki
University of Ottawa | Doctorate Degree |
Statistics
International
Canada | 8 |
United States | 2 |
Operational
Founder | 4 |
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
FATE THERAPEUTICS, INC. | Health Technology |
SATELLOS BIOSCIENCE INC. | Health Technology |
Private companies | 5 |
---|---|
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute Hospital/Nursing ManagementHealth Services The Ottawa Hospital Research Institute is based in Ottawa, CA. The Canadian company provides world-class care with compassionate people. | Health Services |
Verio Therapeutics, Inc.
Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Health Technology |
The Ontario Institute For Regenerative Medicine
The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada. | Commercial Services |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
Stem Cell Network |
- Stock Market
- Insiders
- Michael Rudnicki
- Experience